Access to quality raw materials and increased stakeholder collaboration are needed to help ensure availability of monoclonal antibody (mAb) treatments for COVID-19 in low- and middle-income countries (LMICs).
Standards play an important role in the global medicines supply chain, helping governments and manufacturers increase the availability of safe, quality medicines, as well as building patient and health provider trust. In fact, quality standards are a big reason why we in the U.S. can get a prescription filled at our neighborhood pharmacy and trust that the medicine we receive will be safe and work as it should.
USP’s success in its mission to improve global public health through creation of standards and related programs depends in large part on the work of volunteers.
In simple terms, risk is the possibility of something bad happening. It’s the uncertainty around the consequences of an activity with respect to something that we value.
During the COVID-19 pandemic, we have become acutely aware of how precious time is and the potential repercussions of delays or inefficiencies.
As African nations begin to ease lockdown restrictions, health systems are bracing to prevent the novel coronavirus from spreading rapidly through their populations.
Antimicrobial resistance (AMR) is a global health challenge which can undermine standard treatments and procedures on which we have come to rely.